Wolverine Trading
AIMT

Wolverine Trading’s Aimmune Therapeutics AIMT Stock Holding History

Wolverine Trading’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,525
Closed -$281K – 5545
2020
Q1 		$240K Sell
16,525
-163
-1% -$4.17K ﹤0.01% 3480
2019
Q4 		$560K Buy
+16,688
New +$467K ﹤0.01% 2970

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wolverine Trading's AIMT Position: Q2 2020 in Review

Wolverine Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 16,525 shares — an estimated $281K sold.

Wolverine Trading first reported a position in AIMT in Q4 2019 and held it in 2 quarters. The position peaked at $560K in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Wolverine Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Wolverine Trading sold 16,525 Aimmune Therapeutics shares in Q2 2020, an estimated $281K.
  • Wolverine Trading first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 2 quarters.
  • Wolverine Trading's Aimmune Therapeutics position peaked at $560K in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Wolverine Trading's 13F filing for Q2 2020, filed 13 Aug 2020.